

Product Name : Mivebresib

Synonyms : ABBV-075;ABBV075

Cat No. : M11890

CAS Number : 1445993-26-9

Molecular Formula : C22H19F2N3O4S

Formula Weight : 459.47

Chemical Name : Ethanesulfonamide, N-[4-(2,4-difluorophenoxy)-3-(6,7-dihydro-6-methyl-7-oxo-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl]-

Mivebresib (ABBV-075) is a potent and orally available BET bromodomain inhibitor with Ki of 1.0, 12.2, 1.5, and 2.2 nM for BRD2, BRD3, BRD4 and BRDT, respectively; displays 54-fold selectivity over EP300, has potential weak activity against

Description : SMARCA4 (70% inhibition at 1 uM), Kd >1 uM for 18 other bromodomains; exhibits inhibition of c-Myc expression and

displacing BRD4 from the Myc promoter; dose-dependently inhibits IL-6 concentration in a murine model of LPS-induced endotoxic shock, shows vivo antitumor efficacy in a Kasumi-1 AML mouse xenograft model. Breast Cancer Phase 1 Clinical

Pathway : Chromatin/Epigenetic

Target : Bromodomain

Receptor : BET

Solubility : DMSO: ≥ 37 mg/mL

SMILES : CCS(=0)(NC1=CC=C(OC2=CC=C(F)C=C2F)C(C3=CN(C)C(C4=C3C=CN4)=O)=C1)=O

Storage : (-20°C)

Stability : ≥ 2 years

Reference :

1. McDaniel KF, et al. J Med Chem. 2017 Oct 26;60(20):8369-8384.